News
Aspen, Bambusa close IPOs as Corxel takes SPAC route
Aspen Neuroscience and Bambusa Therapeutics get their Nasdaq IPOs over the line, while Corxel eyes a debut via a blank-cheque company merger.
News
Sanofi eyeing pipeline deals ahead of Dupixent patent loss
Sanofi's CEO says adding to the group's pipeline through M&A and licensing will be "critical" as it prepares for generic competition to Dupixent.
News
AZ seeking $1.5bn in annual savings by end-2029
AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
R&D
Navigating geopolitical risks: Practical and legal mitigatio...
Geopolitical risk is now front of mind for many pharmaceutical leaders.
News
Flagship joins three biotechs together to form Etcelera
Flagship Pioneering has formed a new AI-focused biotech company, called Etcelera, by combining the platforms of three firms from its portfolio.
Debates & Insights
News
Press Releases
Editor's Picks
Editor's Picks
